Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Sponsor: Samsung Medical Center
Summary
This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Official title: Spatial Transcriptomic Approach for Revealing the Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Key Details
Gender
FEMALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-03-18
Completion Date
2027-12-31
Last Updated
2024-03-26
Healthy Volunteers
Yes
Conditions
Interventions
GeoMx data analysis with clinical outcome
1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome
Locations (1)
Ji-Yeon Kim
Seoul, South Korea